STOCK TITAN
  1. Home
  2. Sec-filings
  3. JBIO
  4. [Form 4] Jade Biosciences, Inc. Insider Trading Activity

Jade Biosciences (JBIO) awards RSUs and stock options to legal chief

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jade Biosciences, Inc. granted equity awards to Chief Legal Officer and Corporate Secretary Elizabeth Balta. On February 12, 2026, she received 28,125 shares of common stock in the form of restricted stock units at $0 per share and a stock option for 168,750 shares with a $14.81 exercise price.

The RSUs vest in four equal parts on each of the first four anniversaries of February 15, 2026, if she remains in service. The option vests 25% on February 15, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, also contingent on continued service.

Positive

  • None.

Negative

  • None.
Insider Balta Elizabeth
Role See Remarks
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 168,750 $0.00 --
Grant/Award Common Stock 28,125 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 168,750 shares (Direct); Common Stock — 28,125 shares (Direct)
Footnotes (1)
  1. Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Balta Elizabeth
(Last) (First) (Middle)
C/O JADE BIOSCIENCES, INC.
221 CRESCENT ST., BLDG. 23, STE. 105
(Street)
WALTHAM MA 02453
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Jade Biosciences, Inc. [ JBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/12/2026 A 28,125(1) A $0 28,125 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $14.81 02/12/2026 A 168,750 (2) 02/11/2036 Common Stock 168,750 $0 168,750 D
Explanation of Responses:
1. Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
2. This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Remarks:
Chief Legal Officer and Corporate Secretary
/s/ Elizabeth Balta 02/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Jade Biosciences (JBIO) report for Elizabeth Balta?

Jade Biosciences reported equity grants to Chief Legal Officer Elizabeth Balta. She received 28,125 restricted stock units and a stock option for 168,750 shares, both awarded on February 12, 2026, as part of her compensation package.

What are the key terms of the Jade Biosciences (JBIO) stock option grant?

The stock option covers 168,750 shares of Jade Biosciences common stock at a $14.81 exercise price. One quarter vests on February 15, 2027, and the remaining three quarters vest in equal monthly installments over the following three years, subject to continued service.

Is the Jade Biosciences (JBIO) insider transaction a market purchase or an equity grant?

The insider transaction is an equity grant, not a market purchase. Both the 28,125 RSUs and the option for 168,750 shares were awarded at no cash cost to the insider as compensation, with vesting tied to ongoing service at Jade Biosciences.

Who is the Jade Biosciences (JBIO) insider receiving these equity awards?

The equity awards were granted to Elizabeth Balta, who serves as Chief Legal Officer and Corporate Secretary of Jade Biosciences. The Form 4 identifies her as an officer, with all reported holdings in these awards shown as directly owned.

How does vesting work for the Jade Biosciences (JBIO) RSUs and options?

The RSUs vest in four equal annual tranches starting on the first anniversary of February 15, 2026. The option vests 25% on February 15, 2027, with the remaining 75% vesting monthly over three years, all conditioned on continued service.